CRF Receptor Types and Drug Development for Anxiety and Stress Disorders
Three distinct CRF receptor subtypes and a CRF-binding protein regulate stress responses, and new non-peptide CRF antagonists show promise for treating anxiety, depression, and other CNS disorders.
Quick Facts
What This Study Found
Three CRF receptor subtypes (CRF1, CRF2alpha, CRF2beta) and a CRF-binding protein coordinate stress responses, and newly developed non-peptide CRF antagonists show therapeutic promise.
Key Numbers
How They Did This
Review of molecular biology, pharmacology, and neuroscience literature on CRF receptors, CRF-binding protein, and early CRF antagonist drug development.
Why This Research Matters
CRF is the master regulator of the body's stress response. Understanding its receptor subtypes and developing targeted antagonists could lead to fundamentally new treatments for anxiety and depression.
The Bigger Picture
CRF receptor research has been central to the neuroscience of stress and anxiety. The development of CRF antagonists represented a paradigm shift in thinking about stress-related psychiatric disorders.
What This Study Doesn't Tell Us
Review article from 1996; CRF antagonist drug development was still in early stages. Some therapeutic predictions may not have been borne out in subsequent clinical trials.
Questions This Raises
- ?Will CRF receptor antagonists prove effective in clinical trials for anxiety and depression?
- ?Which CRF receptor subtype is the optimal therapeutic target for different stress-related disorders?
Trust & Context
- Key Stat:
- 3 receptor subtypes identified CRF1, CRF2alpha, and CRF2beta receptors coordinate the body's stress response through cAMP signaling
- Evidence Grade:
- Moderate evidence from a comprehensive review of molecular and pharmacological research. Drug development claims were early-stage at time of publication.
- Study Age:
- Published in 1996, this review captures an important moment in CRF receptor research. Subsequent clinical trials of CRF antagonists showed mixed results.
- Original Title:
- Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.
- Published In:
- Molecular psychiatry, 1(4), 265-77 (1996)
- Authors:
- Behan, D P, Grigoriadis, D E(2), Lovenberg, T, Chalmers, D, Heinrichs, S, Liaw, C, De Souza, E B
- Database ID:
- RPEP-00354
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is CRF?
Corticotropin-releasing factor is the brain's primary stress peptide. Released from the hypothalamus, it triggers the cascade that leads to cortisol release and the 'fight or flight' response. It also directly affects mood, anxiety, and behavior.
Why are CRF antagonists potentially useful?
By blocking CRF receptors, these drugs could theoretically reduce the excessive stress response seen in anxiety disorders and depression. Unlike current anti-anxiety drugs (benzodiazepines), CRF antagonists would target the root cause of stress signaling rather than just dampening its symptoms.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00354APA
Behan, D P; Grigoriadis, D E; Lovenberg, T; Chalmers, D; Heinrichs, S; Liaw, C; De Souza, E B. (1996). Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.. Molecular psychiatry, 1(4), 265-77.
MLA
Behan, D P, et al. "Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.." Molecular psychiatry, 1996.
RethinkPeptides
RethinkPeptides Research Database. "Neurobiology of corticotropin releasing factor (CRF) recepto..." RPEP-00354. Retrieved from https://rethinkpeptides.com/research/behan-1996-neurobiology-of-corticotropin-releasing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.